Continuous Glucose Monitoring Profiles and Health Outcomes after Dapagliflozin Plus Saxagliptin vs Insulin Glargine.

Donald C SimonsonMarcia A TestaElla EkholmMaxwell SuTina VilsbøllSerge A JabbourMarcus Lind

Published in: The Journal of clinical endocrinology and metabolism (2024)

DAPA+SAXA and INS were equally effective in reducing HbA1c at 24 weeks, but people with T2D treated with DAPA+SAXA achieved greater time in range, greater reductions in glycemic excursions and variability, less time with hypoglycemia, and improved patient-reported health outcomes.

Keyphrases

patient reported
glycemic control
type diabetes
weight loss
insulin resistance
newly diagnosed
gestational age
adipose tissue
preterm birth